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Serum Human Chorionic Gonadotropin Concentrations
Greater than 400,000 IU=L Are Invariably Associated
with Suppressed Serum Thyrotropin Concentrations
Christina M. Lockwood,1 David G. Grenache,2,3 and Ann M. Gronowski1

Background: During pregnancy, when human chorionic gonadotropin (hCG) concentrations are highest, there is
a transient suppression of serum thyrotropin (TSH). In normal pregnancy, TSH concentrations generally remain
within nonpregnant reference intervals; however, in some patients TSH is suppressed. Here we sought to extend
previous studies to examine the relationship between very high serum concentrations of hCG (>200,000 IU=L)
and the thyroid hormones TSH and free thyroxine (FT4). The objective of this study was to determine: 1) if there
is an hCG concentration above which TSH concentrations are suppressed (0.2 mIU=mL); 2) how thyroid
hormone concentrations change in response to changes in hCG concentrations; and 3) the clinical symptoms in
patients with such extremely elevated hCG concentrations.
Methods: Residual specimens sent to the laboratories for physician-ordered hCG testing were utilized. Over 26
months, 15,597 physician-ordered hCG tests were performed. Sixty-nine specimens from 63 women with hCG
concentrations >200,000 IU=L were identified, and TSH and FT4 concentrations were measured. Medical records
were reviewed for clinical information.
Results: Thirty-seven percent of subjects had hyperemesis gravidarum (HG) and 19% had gestational trophoblastic disease (GTD). TSH was suppressed (0.2 mIU=mL) in 67% of the specimens with hCG concentrations
>200,000 IU=L and 100% of specimens with hCG concentrations >400,000 IU=L. FT4 concentrations were elevated above the reference interval (1.8 ng=dL) in 32% of specimens with hCG concentrations >200,000 IU=L and
in 80% of specimens with hCG concentrations >400,000 IU=L. Only four subjects had documented signs of
hyperthyroidism. Women with GTD had a median hCG concentration twofold higher than women with HG and
a median TSH concentration one half that of women with HG.
Conclusions: 1) At hCG concentrations >400,000 IU=L, TSH is consistently suppressed; 2) serum FT4 and TSH
respond to changes in serum hCG concentrations; and 3) most patients with hCG concentrations >200,000 IU=L
lack overt hyperthyroid symptoms.

Introduction

T

he association between elevated human chorionic
gonadotropin (hCG) and suppressed thyrotropin (TSH)
concentrations during pregnancy has been known for many
years (1,2). Numerous studies have documented the thyrotropic effect of hCG (1,3–9) and in 1995, Kosugi and Mori (10)
demonstrated that hCG can bind TSH receptors and suppress
TSH production.

In normal pregnancy, TSH suppression is a transient phenomenon and TSH concentrations generally remain within
nonpregnant reference intervals; however, in some women,
TSH may be suppressed below the nonpregnant reference
interval (11,12). Glinoer (13) has proposed that, in order to
trigger excessive production of thyroid hormones, circulating
concentrations of hCG would need to exceed 50,000–75,000
IU=L for an extended period of time (i.e., longer than 1 week)
(13). This threshold was calculated from a prospective study
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correlating hCG, TSH, and free thyroxine (FT4) in pregnant
women, in which a 10,000 IU=L hCG increase corresponded to
a mean FT4 increase of 0.1 ng=dL and a mean TSH decrease
of 0.1 mIU=mL (2). Consequently, the most often cited value
for serum hCG potentially exerting thyrotropic action is
>50,000 IU=L. In a preliminary study, we found that *40%
(19=50) of subjects with hCG concentrations >50,000 IU=L
have suppressed (0.2 mIU=mL) serum TSH concentrations
(14). In addition, we have reported that if there is an hCG
concentration above which all serum TSH concentrations can
be expected to be suppressed, it is >330,000 IU=L (14). However, our study was limited because it contained very few
specimens with hCG concentrations >200,000 IU=L (n ¼ 18).
Recently, Haddow et al. (15) examined the relationship
between hCG and the thyroid hormones TSH and hCG in
9562 women being screened for aneuploidy (15). They reported a weak correlation between hCG and TSH in both first
and second trimesters. They found that TSH was suppressed
when the ratio of hCG to TSH was 200,000. They also found
that women with higher baseline TSH are less likely to experience suppressed TSH at any hCG concentration. Unfortunately, only a small number of their subjects had hCG
concentrations >200,000 IU=L and only about five were
>300,000 IU=L.
Here we sought to extend previous studies by us and others
to examine the relationship between very high serum concentrations of hCG (>200,000 IU=L) and the thyroid
hormones TSH and FT4. In particular, the three specific aims
were to determine: 1) if there is an hCG concentration above
which TSH concentrations were consistently suppressed to
0.2 mIU=mL; 2) how thyroid hormone concentrations change
in response to changes in hCG concentrations; and 3) the
clinical symptoms in patients with hCG concentrations
>200,000 IU=L. This information is important so that clinicians can be familiar with the expected biochemical and
clinical findings in patients with such extremely elevated hCG
concentrations. To our knowledge, this is the largest study of
its kind.
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TSH, and FT4 were measured at BJH by chemiluminescence
on a Siemens Advia Centaur (Siemens Medical Solutions Diagnostics, Tarrytown, NY). At UNC, concentrations of hCG
were determined by the hCG þ b assay on a Roche Elecsys
2010 (Roche Diagnostics, Indianapolis, IN) immunoassay
analyzer and concentrations of TSH and FT4 were determined
using the Ortho Vitros ECi (Ortho-Clinical Diagnostics, Rochester, NY) according to the manufacturer’s instructions. The
hCG methods have been extensively characterized previously; both assays recognize hyperglycosylated hCG, hCGb, and
nicked hCG (16). The dynamic range of each assay was as
follows: Siemens Centaur TSH ¼ 0.02–150 mIU=mL, FT4 ¼ 0.1–
12 ng=dL; Ortho Vitros ECi TSH ¼ 0.01–100 mIU=mL, FT4 ¼
0.0–6.99 ng=dL.
Results
In order to obtain at least 60 subjects with serum hCG
concentrations >200,000 IU=L, 15,597 physician-ordered hCG
tests were performed at the two institutions (9777 at BJH and
5820 at UNC) over a 26-month period at BJH and a 13-month

Materials and Methods
Study subjects
This study was a collaborative, cohort study between
Washington University=Barnes Jewish Hospital (BJH) in St.
Louis and the University of North Carolina=UNC Hospitals in
Chapel Hill, North Carolina. Residual specimens sent to the
BJH and UNC laboratories for physician-ordered hCG testing
were utilized. Our goal was to accrue at least 60 female subjects with hCG >200,000 IU=L for which sufficient specimen
volume was available for additional measurements of TSH
and FT4. Medical records were reviewed for each subject to
establish the subject’s clinical thyroid status and document
the presence of molar, trophoblastic, or other abnormal
pregnancy. This study received approval from the Institutional Review Board of each institution.
Hormone analysis
Physician-ordered hCG testing was performed upon receipt of the specimen in the laboratory. Specimens with hCG
>200,000 IU=L were refrigerated for 3 days before TSH and
FT4 testing was performed. The concentrations of serum hCG,

FIG. 1. Scatter plots of the relationship between serum
human chorionic growth hormone (hCG) and (A) thyrotropin (TSH) and (B) free thyroxine (FT4) concentrations in 69
specimens from 63 women. Dotted horizontal lines represent
the TSH cutoff of 0.2 mIU=mL and upper reference interval
for FT4 of 1.8 ng=dL. Vertical line represents hCG concentration of 400,000 IU=L.
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Table 1. Serum Human Chorionic Gonadotropin and Thyroid Hormone Concentrations and Clinical History
in Ten Specimens from Eight Women with Serum Human Chorionic Gonadotropin Greater than 400,000 IU=L
Study
ID

Gestational
age

hCG
(IU=L)

TSH
(mIU=mL)

FT4
(ng=dL)

Clinical
history
Hyperemesis gravidarum
Twin gestation
Molar pregnancy
Hyperthyroid symptoms
Hyperemesis gravidarum
Molar pregnancy

A50

5 weeks

408,000

0.04

1.94

A14

18 weeks

462,000

<0.02

2.34

A2
A31 #1
A31 #2
B14
B10
A3
B11 #1

9 weeks
7 weeks
8 weeks
N=A
N=A
20 weeks
N=A

471,000
636,000
851,000
655,000
783,000
1,048,000
1,460,000

<0.02
<0.02
<0.02
0.20
<0.01
<0.02
<0.01

2.17
1.95
3.10
1.32
3.03
1.65
3.25

B11 #2

1 day after
specimen #1

550,015

<0.01

2.62

Choriocarcinoma
Molar pregnancy
Molar pregnancy
Molar pregnancy
Hyperthyroid symptoms

N=A, not available.

period at UNC. Of those, 0.4% of specimens (69=15,597) from
63 women with serum hCG concentration >200,000 IU=L
were identified (n ¼ 55 specimens from 52 women at BJH;
n ¼ 14 specimens from 11 women at UNC). Review of the
subjects’ medical records revealed that of the 63 subjects, 37%
(23=63) were diagnosed with hyperemesis gravidarum (HG)
and 19% (12=63) had gestational trophoblastic disease (GTD),
including benign and malignant conditions of hydatidiform
mole as well as choriocarcinoma with or without HG. The remaining 44% (28=63) of patients were pregnant women presenting with threatened abortion (n ¼ 10), vaginal bleeding=
spotting (n ¼ 9), abdominal pain (n ¼ 3), or other reason but
had normal intrauterine pregnancy (n ¼ 6). Ten percent of the
total population (6=63) was pregnant with twins (five of
which had HG; one had a threatened abortion). No subject
had a prior diagnosis of hyperthyroidism noted in her medical
records. Gestational ages ranged from 4 to 20 weeks.
The relationship between serum hCG and serum thyroid
hormone concentrations is shown in Fig. 1. In this population
of specimens with hCG concentrations >200,000 IU=L, 67%
(46=69) demonstrated a suppressed serum TSH 0.2 mIU=mL
(Fig. 1A). Among the specimens with hCG concentrations
>400,000 IU=L, 100% (10=10) of serum TSH concentrations
were suppressed to 0.2 mIU=mL and 90% (9=10) were suppressed below 0.05 mIU=mL. Of the 10 specimens with hCG

>400,000 IU=L, 7 were from women with molar pregnancies,
1 was from a woman with choriocarcinoma, and 2 were from
pregnancies with HG (Table 1).
As depicted in Fig. 1B, only 33% (23=69) of the 69 specimens
had elevated FT4 concentrations above the reference interval
(0.9–1.8 ng=dL). Among the specimens with hCG concentrations >400,000 IU=L, 80% (8=10) were >1.8 ng=dL. Of the two
subjects with FT4 concentrations within the normal reference
intervals, one subject (B14) was diagnosed with choriocarcinoma and also exhibited the greatest TSH concentration
(0.20 mIU=mL) among specimens with hCG >400,000 IU=L.
Subject A3 was diagnosed with a complete molar pregnancy
and although her FT4 concentration was within the normal
reference interval, it was quite high at 1.65 ng=dL with a
corresponding TSH suppressed to <0.02 mIU=mL.
Median serum TSH and FT4 concentrations for the entire
study population and subgroups with serum hCG concentrations below or above 400,000 IU=L are shown in Table 2. There
were notable differences between serum TSH and FT4 concentrations in subjects with hCG concentrations >400,000 IU=L
as compared to subjects with hCG concentrations between
200,000 and 400,000 IU=L. Despite these differences in thyroid
hormone concentrations, clinical signs and symptoms of hyperthyroidism were noted in only 4=63 (6%) subjects, two of
which had hCG concentrations >400,000 IU=L.

Table 2. Serum Thyrotropin, Free Thyroxine, and Human Chorionic Gonadotropin
Concentrations in Various Subgroups
Median hCG
(range) IU=L

Study group

N

All specimens
hCG 200,000–400,000 IU=L
hCG >400,000 IU=L
Gestational trophoblastic
disease
Hyperemesis gravidarum
All other diagnoses

69
59
10
16

246,106
239,398
645,647
423,542

25
28

243,970 (205,798–470,816)
226,155 (200,302–313,408)

(200,302–1,459,892)
(200,302–385,305)
(407,674–1,459,892)
(261,749–1,459,892)

Median FT4
(range) ng=dL
1.45
1.14
2.26
1.97

(0.91–4.19)
(0.91–4.19)
(1.32–3.25)
(1.08–3.25)

1.51 (1.08–4.19)
1.24 (0.91–1.99)

Nonpregnant reference intervals: TSH ¼ 0.35–5.5 mIU=mL; FT4 ¼ 0.9–1.8 ng=dL.

Median TSH
(range) mIU=mL
0.07
0.08
0.02
0.02

(0.01–8.15)
(0.01–8.15)
(0.01–0.20)
(0.009–1.35)

0.04 (0.019–2.09)
0.22 (0.009–8.15)

% with suppressed
TSH (0.2 mIU=mL)
67%
61%
100%
88%

(46=69)
(36=59)
(10=10)
(14=16)

76% (19=25)
46% (13=28)
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FIG. 2. Scatter plot of the relationship between serum TSH
and FT4 concentrations in 69 specimens from 63 women with
hCG concentrations >200,000 IU=mL. Dotted lines represent
the TSH cutoff of 0.2 mIU=mL and upper reference interval
for FT4 of 1.8 ng=dL. GTD, gestation trophoblastic disease;
other, non-GTD and non-hyperemesis patients.

Median serum TSH and FT4 concentrations for women
with GTD and HG are also shown in Table 2. The median TSH
concentration of the GTD group was half that of the HG group
and 10-fold less than non-GTD and non-HG patients. In addition, median hCG concentrations were nearly two times
greater in women with GTD than the median hCG concentrations for women with HG or other diagnoses. Eightyeight percent of women with GTD demonstrated suppressed
TSH concentrations 0.2 mIU=mL.
The relationship between serum TSH and FT4 in subjects
with hCG concentrations >200,000 IU=L is shown in Fig. 2.
These data demonstrate the expected inverse relationship
between TSH and FT4. Of the 69 specimens, 32% (22=69) had
both low TSH and elevated FT4.
Five subjects were found with serum hCG >200,000 IU=L
on more than one occasion and therefore multiple measurements on a single subject were captured in the study, allowing
us to assess how thyroid hormones change in response to
changing hCG concentrations. Two subjects (A31 and B11) are
shown in Table 1. The laboratory results for the other three
subjects (A5, A7, and B7) are shown in Table 3. The hCG
concentration of subject A31, who was diagnosed with a
complete molar pregnancy (Table 1), increased 215,000 IU=L

(34%) over 5 days. Correspondingly, the FT4 increased from
1.95 to 3.1 ng=dL (59%), while the TSH remained <0.02
mIU=mL. One week after the mole was removed, the subject’s
hCG concentration had decreased to 7597 IU=L with a corresponding decrease in the FT4 concentration to within the
reference interval (1.5 ng=dL), though the TSH remained
suppressed (<0.02 mIU=mL). The hCG concentration of subject B11 decreased 62% in a single day following molar removal with a 19% decrease in FT4 (3.25 to 2.62 ng=dL) in that
same time period. The hCG concentration of subject A5, who
was diagnosed with HG, decreased by 37,000 IU=L (13%) in
the 5 weeks separating the laboratory measurements and a
corresponding decrease in FT4 concentration was observed
from 4.19 to 3.99 ng=dL (4%) while the TSH remained
<0.02 mIU=mL. Another subject with HG (A7) demonstrated a
54,000 IU=L (23%) increase in hCG concentration over 10 days
and, over that period, the FT4 concentration increased from
1.51 to 2.25 ng=dL (49%) and TSH decreased from 0.14 to
<0.02 mIU=mL (>86%). Subject B7, diagnosed with a complete
hydatidaform mole, exhibited an hCG concentration increase
of 112,000 IU=L (43%) in 1 week with a 6% increase in FT4 and
a corresponding 31% decrease in TSH concentration (1.35 to
0.925 mIU=mL).
Comment
Here, we sought to determine whether a threshold serum
hCG concentration exists above which serum TSH concentration can be expected to be suppressed to 0.2 mIU=mL
100% of the time. In subjects with hCG concentrations
>200,000 IU=L, serum TSH was suppressed in 67% (46=69) of
specimens and serum FT4 was elevated above the reference
interval (1.8 ng=dL) in 33% (23=69) of specimens. Among the
specimens with hCG concentrations >400,000 IU=L, 100%
(10=10) of serum TSH concentrations were suppressed 0.2
mIU=mL and 80% (8=10) of serum FT4 concentrations were
elevated >1.8 ng=dL.
What causes hCG to have thyrotropic effects in some women but not others is not clear. Some have proposed that it is
due to the absolute hCG concentration (1,13). Others have
suggested that the length of time hCG is elevated plays a role
(13). Still others have suggested that differences in hCG glycosylation or sialylation that is seen in patients with GTD and
HG results in increased thyrotropic activity (6,17–20). In the
present study, it is clear that absolute hCG concentrations are
higher in women with GTD. Women with GTD also demonstrated much lower TSH concentrations with 88% of GTD
patients having suppressed TSH 0.2 mIU=mL. It is unclear

Table 3. Serum Human Chorionic Gonadotropin and Thyroid Hormone Concentrations and Clinical
History in Three Women with Serial Serum Human Chorionic Gonadotropin Greater than 200,000 IU=L
Study
ID

Gestational
age

hCG
IU=L

TSH
mIU=mL

FT4
ng=dL

A5 #1
A5 #2
A7 #1
A7 #2
B7 #1
B7 #2

8 weeks
12 weeks
7 weeks
9 weeks
N=A
7 days after
specimen #1

286,000
249,000
238,000
292,000
261,749
373,680

<0.02
<0.02
0.14
<0.02
1.35
0.93

4.17
3.99
1.51
2.25
1.26
1.34

Clinical history
Hyperemesis gravidarum
Hyperemesis gravidarum
Molar pregnancy
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from this study if length of hCG elevation or hCG variant also
played a role in the thyrotropic activities. However, it is clear
that patients with GTD are at a higher risk for hCG concentrations >400,000 IU=L, suppressed TSH, and clinically apparent hyperthyroidism.
Haddow et al. (15) reported that in their population of 9562
pregnant women TSH was substantially suppressed when the
ratio of hCG to TSH was 200,000. In our study, 88% (61=69)
of specimens had hCG=TSH ratios >200,000. Of these, 74%
(45=61) had TSH concentrations <0.2 mIU=mL. In our population, specimens with TSH concentrations <0.2 mIU=mL (n ¼
45) had hCG=TSH ratios 1.4 million.
This study identified five subjects with more than one
specimen with hCG concentration >200,000 IU=L (shown in
Tables 1 and 3). Although the number of these subjects was
limited, they further illustrate the relationship between hCG
and the thyroid hormones. As hCG concentrations changed,
in all cases TSH and FT4 changed in a predictable manner,
with FT4 changing more rapidly than TSH.
The majority of women in our study (94%, 59=63) did not
have any overt signs or symptoms of hyperthyroidism reported in their medical record. Only two subjects with GTD
(A14, B11) exhibited signs of hyperthyroidism with peak hCG
concentrations of 462,000 and 1,460,000 IU=L respectively
(Table 1). The clinical history, physical signs, and laboratory
data for these two subjects were all compatible with hyperthyroidism. This data supports the idea that clinical symptoms should take precedence over biochemical measurements
in these patients.
One limitation of this study is that each subject was not
carefully examined for subtle signs of hyperthyroidism.
However, medical records were reviewed with attention to
heart rate, blood pressure, and any other signs of hyperthyroidism. It is possible that subtle signs and symptoms were
missed, but clearly these subjects were clinically euthyroid
when evaluated.
In this group of subjects with extremely elevated hCG
concentrations (>200,000 IU=L), the inverse relationship between TSH and FT4 was similar to that found in hCG-negative
subjects. It is interesting to note that of the 46 specimens in our
study with suppressed TSH, 48% (22=46) had normal FT4
concentrations. This likely reflects the well-known log-linear
relationship between TSH and FT4 whereby small changes in
FT4 produce large changes in TSH (21).
Recently, the FaSTER Research Consortium reported the
need for gestational age-specific reference intervals for TSH
and FT4 (22). In that study of nearly 10,000 subjects, the lower
5th centile for TSH in the first trimester was shown to be
0.13 mIU=mL and the upper 95th centile for FT4 in the first
trimester was 1.38 ng=dL. Applying these cutoffs to the population described here, 90% (9=10) of subjects with hCG
concentrations >400,000 IU=L demonstrated suppressed TSH
and elevated FT4 concentrations. Only one subject (B14) with
a choriocarcinoma did not demonstrate abnormal thyroid
hormone concentrations.
This study examined the physiological relationship between
extremely high serum concentrations of hCG (>200,000 IU=L)
and thyroid hormones. We have demonstrated that: 1) at hCG
concentrations >400,000 IU=L, TSH is consistently suppressed
0.2 mIU=mL; 2) serum FT4 and TSH concentrations change as
expected in response to changes in serum hCG concentrations;
and 3) most patients with extremely elevated hCG concen-
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trations have no overt signs and symptoms of hyperthyroidism despite altered thyroid hormone measurements.
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